Generic placeholder image

Current Bioinformatics


ISSN (Print): 1574-8936
ISSN (Online): 2212-392X

Research Article

Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer

Author(s): Jian Li, Zheng Gong, Haicheng Jiang, Jie Gao, Jianwei Liang, Peng Chang and Yulong Hou*

Volume 16, Issue 1, 2021

Published on: 30 May, 2020

Page: [130 - 138] Pages: 9

DOI: 10.2174/1574893615999200530201333

Price: $65


Background: Non-small cell lung cancer (NSCLC) is one of the most leading cause of tumor related mortality worldwide. However, the prognosis of NSCLC remained to be poor and the mechanisms remained to be further investigated.

Objective: This study aimed to evaluate whether GPRIN1 could be a potential biomarker for NSCLC.

Methods: The Cancer Genome Atlas (TCGA, and GEO database( were used to analyze the GPRIN1 expression between normal and human cancers. The protein-protein interaction among centromere proteins was determined using STRING database ( GraphPad Prism 5.0 software was utilized for the independent and paired samples’ t-test or ANOVA to analyze the difference of GPRIN1 expression between two groups.

Results: This study showed GPRIN1 was overexpressed and correlated to shorter OS time in human cancers. In NSCLC, we found that GPRIN1 was up-regulated in NSCLC samples compared to normal lung tissues by analyzing TCGA and GEO datasets. Bioinformatics analysis indicated that this gene was involved in regulating cancer proliferation and metabolism. Finally, we identified key targets of GPRIN1 in NSCLC by constructing PPl networks, including MCM3, KIF20A, UHRF1, BRCA1, KIF4A, HMMR, KIF18B, KIFC1, ASPM, and NCAPG2.

Conclusion: These analyses showed GPRIN1 could act as a prognosis biomarker in patients with NSCLC.

Keywords: Non-small cell lung cancer, GPRIN1, prognosis, biomarker, protein, bioinformatics analysis.

Graphical Abstract
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[] [PMID: 30207593]
Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet 2013; 382(9893): 709-19.
[] [PMID: 23972814]
Nakata H, Kozasa T. Functional characterization of Galphao signaling through G protein-regulated inducer of neurite outgrowth 1. Mol Pharmacol 2005; 67(3): 695-702.
[] [PMID: 15585744]
Guo Z, Neilson LJ, Zhong H, Murray PS, Zanivan S, Zaidel-Bar R. E-cadherin interactome complexity and robustness resolved by quantitative proteomics. Sci Signal 2014; 7(354): rs7.
[] [PMID: 25468996]
Wong SHM, Fang CM, Chuah LH, Leong CO, Ngai SC. Ecadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol 2018; 121: 11-22.
[] [PMID: 29279096]
Yu Q, Guo Q, Chen L, Liu S. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review. Drug Des Devel Ther 2015; 9: 2171-8.
[PMID: 25931811]
de Hoog CL, Foster LJ, Mann M. RNA and RNA binding proteins participate in early stages of cell spreading through spreading initiation centers. Cell 2004; 117(5): 649-62.
[] [PMID: 15163412]
Zhang Z, Peng Z, Cao J, et al. Long noncoding RNA PXN-AS1-L promotes non-small cell lung cancer progression via regulating PXN. Cancer Cell Int 2019; 19: 20.
[] [PMID: 30679933]
Jiang H, Zhang H, Hu X, Li W. Knockdown of long non-coding RNA XIST inhibits cell viability and invasion by regulating miR-137/PXN axis in non-small cell lung cancer. Int J Biol Macromol 2018; 111: 623-31.
[] [PMID: 29337100]
Liu Q, Wang J, Tang M, et al. The overexpression of PXN promotes tumor progression and leads to radioresistance in cervical cancer. Future Oncol 2018; 14(3): 241-53.
[] [PMID: 29318915]
Li D, Li Z, Xiong J, et al. MicroRNA-212 functions as an epigenetic-silenced tumor suppressor involving in tumor metastasis and invasion of gastric cancer through down-regulating PXN expression. Am J Cancer Res 2015; 5(10): 2980-97.
[PMID: 26693054]
Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res 2017; 77(21): e108-10.
[] [PMID: 29092952]
Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 2018; 8(1): 9227.
[] [PMID: 29907753]
Anderson NM, Simon MC. BACH1 orchestrates lung cancer metastasis. Cell 2019; 178(2): 265-7.
[] [PMID: 31257029]
Seiler J, Breinig M, Caudron-Herger M, Polycarpou-Schwarz M, Boutros M, Diederichs S. The lncRNA VELUCT strongly regulates viability of lung cancer cells despite its extremely low abundance. Nucleic Acids Res 2017; 45(9): 5458-69.
[] [PMID: 28160600]
Cheng Z, Yu C, Cui S, et al. circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. Nat Commun 2019; 10(1): 3200.
[] [PMID: 31324812]
Valverde LF, de Freitas RD, Pereira TA, et al. MCM3: a novel proliferation marker in oral squamous cell carcinoma. Appl Immunohistochem Mol Morphol 2018; 26(2): 120-5.
[PMID: 27258565]
Yang Q, Xie B, Tang H, et al. Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway. J Exp Clin Cancer Res 2019; 38(1): 263.
[] [PMID: 31208444]
Huang J, Luo HL, Pan H, Qiu C, Hao TF, Zhu ZM. Interaction between RAD51 and MCM complex is essential for RAD51 foci forming in colon cancer HCT116 Cells. Biochemistry 2018; 83(1): 69-75.
[] [PMID: 29534671]
Wan X, Yang S, Huang W, et al. UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy. J Exp Clin Cancer Res 2016; 35: 34.
[] [PMID: 26884069]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy